Therefore, treatment outcomes will depend on a variety of factors including, but not limited to, the following: specific p53 mutation status, BRCA 1/2 status, resistance to chemotherapy agents and/or PARP inhibitors, biomarkers, tumor origin site, stage, and Ad5-neutralizing antibody immunity status. This evidence concerns the gene PSEN2 and neoplasm.